- Company plans to use proceeds from direct offering for business development, drug repurposing and discovery and expansion of its laboratory facilities
- POAI portfolio spans four different subsidiaries, including list of assets rivaling best operators in the space
- Predictive Oncology is strong standout in precision medicine
Predictive Oncology (NASDAQ: POAI) has closed on its registered direct offering (https://ibn.fm/9buhx).The offering, which totaled $21.34 million, will be a boon for the knowledge-driven company as it continues its focus on applying artificial intelligence (“AI”) to personalized medicine and drug discovery.
Operating in the AI space, the company is looking at almost vast potential as it focuses efforts on personalized medicine and drug discovery. The POAI portfolio is impressive, spanning four different subsidiaries — Helomics, TumorGenesis, Soluble Biotech and Skyline Medical — and including a list of assets that rivals the best operators in the space (https://ibn.fm/knRZc).
Leveraging the unparalleled expertise and rich resources it has assembled, POAI has established one of the largest databases available of clinically validated historical and outcome data from patient tumors, an in-house Clinical Laboratory Improvement Amendments (“CLIA”)-certified lab, and a novel approach to growing tumors in the lab that mimics the tumor in the patient’s own body.
In addition, the company offers several innovative platforms, including a “smart” patient-derived tumor profiling platform; an in-house bioinformatics AI platform; and a comprehensive in silico platform, known as CORE and developed by top researchers from Carnegie Mellon University, that iteratively optimizes predictive models using a guided selection of experiments.
Through its commitment to resources and innovative thinking, POAI has also gained a reputation for its expertise in specializing in media that help cancer cells grow and retain their DNA/RNA and proteomic signatures, a key piece of being able to move forward in personalize medicine, specifically in the cancer space. POAI has also become a recognized provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins and protein complexes, as well as endotoxin detection and removal.
Finally, POAI has developed an FDA-approved fluid collection and disposal system.
This strong portfolio makes POAI a strong standout in precision medicine, where precisely targeting drugs based on the genomic profile of the patient’s tumor, has become the aspiration for cancer therapy. “However, the reality is that while we can find many mutations in the patient’s tumor, most are not actionable with current drugs,” the company observes. “So, the race has begun to generate more data to understand which mutations are associated with what drug, in order to target therapy, a process that can take five to seven years of clinical evaluation to gather outcome data.”
That’s where POAI enters the picture, “leveraging [its] unique, historical database of the drug responses of over 150,000 patient tumors to build data-driven predictive models of tumor drug response. These models will provide actionable insights critical to both new drug development and individualizing patient treatment.
“Predictive Oncology prospectively may have a competitive advantage,” the company concludes. “The company already has a substantial historical database of tumors and related data, plus the ability to obtain the associated outcome data. While others must wait for outcome data, Predictive Oncology is in a unique and powerful position, working to deliver the promise of precision medicine. Predictive Oncology presently has the clinical information, including tumor drug response data and an in-house bioinformatics AI platform.”
POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated patient derived (“PDx”) smart tumor profiling platform to provide oncologists with a roadmap to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of more than 150,000 cancer cases tumors to build AI-driven models of tumor drug response to improve outcomes for the patients of today and tomorrow.
For more information, visit the company’s website at www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.